Please assess the completion status of the following clinical trial:

Trial Title: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women who are 50 years or older~* ≥1 prescription fill for ABL or TPTD during the identification period~* ≥ 1 claim for medical or hospital visit and a pharmacy claim in the 12 months before the index date~Exclusion Criteria:~* Paget's disease~* Malignancy, except for nonmelanoma skin cancers, carcinoma in-situ of the cervix, ductal carcinoma in-situ of breast~* Indicators of high disease burden and high risk of death~* With prior index anabolic treatment~* Switch to a different anabolic treatment after index date

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients Treated with Abaloparatide (Type: None): Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
- Patients Treated with Teriparatide (Type: None): Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.

Based on this trial design, predict the completion outcome and termination type (if applicable).